The Forefront of New Cancer Therapy Research
Some of the most advanced Phase I clinical trials being conducted are offered through the Swim Across America Innovative Clinical Trials Center (ICTC) at Baylor Charles A. Sammons Cancer Center, located on the campus of Baylor University Medical Center, part of Baylor Scott & White Health.
An expansion of the cancer clinical trials offered at Baylor Sammons Cancer Center, our goal for the ICTC is to drive advancements in early cancer detection and new cancer therapy agents through the completion of innovative clinical trials.
What We Do
The ICTC consolidates all Phase I trials, offering participating patients one location for clinical examinations, infusions, imaging studies, sample collections for lab work and follow-up.
Through the leadership of our investigators and collaborations with the US Oncology Research Network, Translational Genomics Research Institute (TGEN), Baylor Scott & White Research Institute and others in the science and medical community, we intend to bring the best options and hope to those who need them.
Phase I clinical trials underway represent possible future treatments for:
- Pancreatic cancer
- Breast cancer
- Blood cancers
- Brain tumors
- Prostate cancer
Swim Across America
The Innovative Clinical Trials Center at Baylor Charles A. Sammons Cancer Center benefits greatly from the support of Swim Across America (SAA), which has a goal to raise more than $1 million over a four-year period for ICTC research. SAA hosts open-water swim events where swimmers chose to swim a half-mile, mile or two-mile course. The participants raise money, competing as a team or individually.
ICTC Study Example
One of our most promising studies funded by SAA has produced some unique developments.
- A sample collection trial has led to a consistent and uniform group of patient blood samples on which to perform testing—a unique feature in medical research.
- This sample suppository has opened the door to a new collaboration with the SALK Institute for Biological Studies in California around biomarker identification to potentially measure a patient’s response to his or her treatments.
- The hope is that there will be a correlation between levels of this biomarker and disease status, thus enabling us to introduce a more accurate form of patient monitoring during the treatment phase.